{"gene":"PKIB","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2000,"finding":"PKIB was cloned as a novel member of the human cAMP-dependent protein kinase inhibitor (PKI) gene family; the deduced protein contains both a pseudosubstrate site and a leucine-rich nuclear export signal motif, consistent with its role as an endogenous inhibitor of PKA catalytic activity. PKIB was mapped to chromosome 6q21-22.1 and shown to have two transcripts with distinct tissue expression patterns.","method":"cDNA cloning, Northern blot, radiation hybrid mapping","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct cloning and structural domain identification with tissue expression characterization, single lab","pmids":["10880337"],"is_preprint":false},{"year":2009,"finding":"PKIB directly interacts with the cAMP-dependent protein kinase A catalytic subunit (PKA-C); this interaction is required for nuclear translocation of PKA-C in prostate cancer cells. Additionally, PKIB promotes phosphorylation of Akt at Ser473 via PKA-C, as demonstrated by an in vitro kinase assay showing recombinant PKIB enhances PKA-C-mediated Akt phosphorylation. Knockdown of PKIB reduced nuclear PKA-C and decreased Akt-Ser473 phosphorylation, while PKIB overexpression enhanced it.","method":"Co-immunoprecipitation, siRNA knockdown, exogenous overexpression, in vitro kinase assay, nuclear fractionation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay plus reciprocal interaction plus functional KD/OE with defined biochemical readouts, single lab with multiple orthogonal methods","pmids":["19483721"],"is_preprint":false},{"year":2014,"finding":"PKIB (protein kinase inhibitor β) was identified as a binding partner of the C-terminus of the G-protein-coupled zinc receptor GPR39 via yeast-two-hybrid screen. Co-expression of PKIB with GPR39 enhanced GPR39's constitutive protective activity via the Gα13/RhoA/SRE pathway. Zinc caused dissociation of PKIB from GPR39, liberating PKIB to associate with PKA and inhibit its activity, forming a negative-feedback loop. Mutation of PKIB's pseudosubstrate domain abolished PKA inhibition but did not affect GPR39 interaction or cell protection.","method":"Yeast-two-hybrid screen, co-expression functional assay, site-directed mutagenesis of pseudosubstrate domain, SRE-reporter assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 — Y2H identification plus mutagenesis plus functional reporter assay, multiple orthogonal methods in single study","pmids":["24869658"],"is_preprint":false},{"year":2015,"finding":"Chronic hyperglycemia activates HIF1-dependent transcription of PKIB in pancreatic islets, and PKIB acts as a potent inhibitor of PKA catalytic activity, thereby disrupting cAMP signaling and impairing beta cell function. Genetic disruption of the PKIB gene improved islet function in obese mice, placing PKIB downstream of HIF1 and upstream of PKA in this pathway.","method":"PKIB knockout mouse model, oral glucose tolerance test, islet functional assays, HIF1-dependent gene induction assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined physiological phenotype, genetic epistasis (HIF1→PKIB→PKA) supported by multiple assays","pmids":["25704817"],"is_preprint":false},{"year":2016,"finding":"PKIB promotes cell proliferation and invasion-metastasis in NSCLC cells through activation of the PI3K/Akt signaling pathway; inhibition of PI3K/Akt abolished the pro-proliferative and pro-metastatic effects of PKIB overexpression, and knockdown of PKIB reduced Akt pathway activity.","method":"MTT assay, BrdU assay, western blot, migration/invasion assays, PI3K inhibitor epistasis experiment, siRNA knockdown and overexpression","journal":"Experimental biology and medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 — pathway epistasis via inhibitor plus KD and OE, single lab","pmids":["27325557"],"is_preprint":false},{"year":2019,"finding":"PKIB expression in aromatase inhibitor-resistant breast cancer is regulated by androgen receptor (AR) downstream of androstenedione signaling; ChIP analysis demonstrated direct AR recruitment to the PKIB gene promoter, and re-exposure to estradiol suppressed PKIB expression.","method":"RNA sequencing, ChIP assay, cell viability assay, hormone treatment/withdrawal experiments","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP directly demonstrates AR binding to PKIB promoter, functional regulation confirmed by hormone manipulation, single lab","pmids":["31289138"],"is_preprint":false},{"year":2020,"finding":"Downregulation of PKIB in placental trophoblasts decreases phosphorylated Akt and downstream proteins (MMP2, MMP9, GSK3β), resulting in impaired trophoblast migration, invasion, and vessel formation. PKIB knockdown by siRNA phenocopied preeclampsia-associated defects in HTR8/SVneo cells.","method":"siRNA knockdown, real-time cell analysis, tube formation assay, spheroid sprouting assay, western blot","journal":"Reproductive sciences","confidence":"Medium","confidence_rationale":"Tier 2–3 — clean KD with multiple functional readouts and defined biochemical mechanism via Akt pathway, single lab","pmids":["32676926"],"is_preprint":false},{"year":2024,"finding":"In castration-resistant prostate cancer, GR (glucocorticoid receptor) transcriptional activity following androgen receptor signaling inhibition directly upregulates PKIB mRNA and protein, leading to nuclear accumulation of PKA catalytic subunit (PKA-c) and increased CREB phosphorylation. SGRM treatment reduced PKIB expression and delayed CRPC progression in xenograft models.","method":"Gene expression analysis, SGRM treatment in xenograft mouse model, PKA-c nuclear localization assessment, CREB phosphorylation western blot","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo xenograft plus biochemical readouts of PKA-c localization and CREB phosphorylation, single lab","pmids":["38030378"],"is_preprint":false},{"year":2025,"finding":"PKIB disrupts PKA kinase activity in bladder cancer cells, resulting in decreased phosphorylation of HSP27 at serine residues 15, 78, and 82 (a PKA substrate). Additionally, the transcription factor MYCN directly binds the PKIB promoter to drive PKIB overexpression in bladder cancer, linking upstream transcriptional regulation to the PKA/HSP27 pathway.","method":"In vitro functional assays (proliferation, migration, invasion), in vivo tumorigenic model, western blot for HSP27 phosphorylation, promoter binding assay for MYCN","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic identification of a specific PKA substrate (HSP27) and upstream transcriptional regulator (MYCN), multiple methods, single lab","pmids":["40593489"],"is_preprint":false}],"current_model":"PKIB is an endogenous inhibitor of the PKA catalytic subunit that contains a pseudosubstrate domain and a nuclear export signal; it directly binds PKA-C to suppress its activity and control its nuclear translocation, while also linking PKA signaling to oncogenic Akt (Ser473) phosphorylation, regulating specific PKA substrates such as HSP27, interacting with GPR39 at the plasma membrane to modulate cAMP feedback, and being transcriptionally induced by HIF1 (in hyperglycemia/islet dysfunction) and by AR/MYCN in cancer contexts."},"narrative":{"teleology":[{"year":2000,"claim":"Cloning of PKIB established it as a third member of the PKI gene family, resolving whether additional PKA inhibitor genes existed beyond PKIA and PKIG and revealing that PKIB encodes both a pseudosubstrate inhibitory domain and a nuclear export signal.","evidence":"cDNA cloning, Northern blot, and radiation hybrid mapping in human tissues","pmids":["10880337"],"confidence":"Medium","gaps":["No direct demonstration of PKA inhibitory activity by recombinant PKIB protein","Nuclear export function of the NES motif was inferred from sequence homology, not tested experimentally","Tissue-specific functional relevance remained uncharacterized"]},{"year":2009,"claim":"Demonstration that PKIB physically binds PKA-C and is required for PKA-C nuclear translocation resolved how PKIB controls PKA localization; the finding that PKIB enhances PKA-C-mediated Akt Ser473 phosphorylation in vitro revealed an unexpected pro-oncogenic link between PKA inhibition and Akt activation.","evidence":"Co-immunoprecipitation, siRNA knockdown, overexpression, in vitro kinase assay, and nuclear fractionation in prostate cancer cells","pmids":["19483721"],"confidence":"High","gaps":["Whether PKIB promotes Akt phosphorylation by directly altering PKA-C substrate specificity or by an indirect mechanism was not resolved","In vivo validation of the PKIB–Akt axis was lacking","Structural basis of the PKIB–PKA-C interaction was not determined"]},{"year":2014,"claim":"Identification of GPR39 as a PKIB-binding partner established a receptor-level mechanism: PKIB is sequestered at GPR39 and released by zinc to inhibit PKA, creating a ligand-gated negative-feedback loop on cAMP signaling.","evidence":"Yeast-two-hybrid screen, co-expression functional assays, pseudosubstrate domain mutagenesis, and SRE-reporter assay","pmids":["24869658"],"confidence":"High","gaps":["Endogenous PKIB–GPR39 interaction was not confirmed by co-IP from native tissue","Physiological tissue context for this feedback loop was not established","Whether other GPCRs similarly sequester PKI family members was unknown"]},{"year":2015,"claim":"Genetic deletion of PKIB improved glucose tolerance in obese mice, establishing PKIB as a physiologically relevant PKA inhibitor in pancreatic islets and placing it in a HIF1→PKIB→PKA pathway that mediates hyperglycemia-induced beta cell dysfunction.","evidence":"PKIB knockout mouse model, oral glucose tolerance tests, islet functional assays, HIF1-dependent gene induction","pmids":["25704817"],"confidence":"High","gaps":["Whether PKIB deletion rescues beta cell mass versus function was not dissected","Relative contributions of PKIA and PKIG in islets were not addressed","Downstream PKA substrates mediating the islet phenotype were not identified"]},{"year":2016,"claim":"Epistasis experiments in NSCLC cells showed that PKIB's pro-proliferative and pro-invasive effects depend on PI3K/Akt pathway activation, generalizing the PKIB–Akt connection beyond prostate cancer.","evidence":"PI3K inhibitor epistasis, siRNA knockdown, overexpression, proliferation, and invasion assays in NSCLC cells","pmids":["27325557"],"confidence":"Medium","gaps":["The direct molecular step linking PKIB/PKA-C to PI3K/Akt activation was not defined","In vivo NSCLC tumor model validation was absent","Single-lab finding without independent replication"]},{"year":2019,"claim":"ChIP analysis demonstrated that the androgen receptor directly binds the PKIB promoter in aromatase inhibitor-resistant breast cancer, establishing the first defined transcription factor that directly drives PKIB expression in a therapy-resistance context.","evidence":"ChIP assay, RNA-seq, hormone manipulation in AI-resistant breast cancer cells","pmids":["31289138"],"confidence":"Medium","gaps":["Functional consequence of AR-driven PKIB on PKA activity in breast cancer was not measured","Whether PKIB is required for AI resistance was not tested by genetic depletion","Single-lab observation"]},{"year":2020,"claim":"PKIB knockdown in trophoblasts reduced pAkt and downstream MMP2/MMP9, impairing migration, invasion, and tube formation, extending the PKIB–Akt axis to placental biology and suggesting a role in preeclampsia pathogenesis.","evidence":"siRNA knockdown, real-time cell analysis, tube formation and spheroid sprouting assays, western blot in HTR8/SVneo cells","pmids":["32676926"],"confidence":"Medium","gaps":["No patient-derived tissue validation of PKIB downregulation in preeclampsia","Whether PKA catalytic activity is involved or the effect is PKA-independent was not tested","Single cell line study"]},{"year":2024,"claim":"In CRPC, glucocorticoid receptor directly upregulates PKIB after AR inhibition, leading to nuclear PKA-C accumulation and CREB phosphorylation; pharmacologic GR antagonism reduced PKIB and delayed CRPC progression, identifying PKIB as a GR-dependent resistance mediator.","evidence":"Gene expression analysis, xenograft mouse model with SGRM treatment, PKA-C nuclear localization and pCREB western blot","pmids":["38030378"],"confidence":"Medium","gaps":["Whether PKIB is sufficient (not just necessary) for GR-driven CRPC resistance was not shown","The paradox of PKIB as a PKA inhibitor yet promoter of nuclear PKA-C and pCREB was not mechanistically resolved","Single-lab finding"]},{"year":2025,"claim":"PKIB was shown to suppress PKA-mediated HSP27 phosphorylation at serines 15, 78, and 82, identifying the first specific PKA substrate regulated by PKIB; MYCN was found to directly bind the PKIB promoter, adding a third oncogenic transcription factor driving PKIB expression.","evidence":"Western blot for HSP27 phospho-sites, promoter binding assay for MYCN, proliferation/migration/invasion assays, in vivo bladder cancer model","pmids":["40593489"],"confidence":"Medium","gaps":["Whether HSP27 dephosphorylation is the primary effector of PKIB-driven bladder cancer phenotypes was not tested","Single-lab finding without independent confirmation of MYCN–PKIB regulation","Structural basis for PKIB selectivity toward HSP27 phosphorylation versus other PKA substrates was not addressed"]},{"year":null,"claim":"The mechanism by which PKIB, nominally a PKA inhibitor, simultaneously promotes nuclear PKA-C translocation and Akt Ser473 phosphorylation remains unresolved; whether these reflect direct allosteric effects on PKA-C, scaffolding functions, or context-dependent conformational switching is unknown.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or biophysical data on the PKIB–PKA-C complex exist","The paradox of PKA inhibition versus nuclear PKA-C accumulation has not been mechanistically reconciled","Whether PKIB functions differently from PKIA and PKIG in any biological context remains untested by direct comparison"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,4,6,7,8]}],"complexes":[],"partners":["PRKACA","GPR39","AKT1","HSPB1"],"other_free_text":[]},"mechanistic_narrative":"PKIB is an endogenous inhibitor of the cAMP-dependent protein kinase A catalytic subunit (PKA-C) that functions through a pseudosubstrate domain and a leucine-rich nuclear export signal to regulate PKA activity and subcellular localization [PMID:10880337, PMID:19483721]. PKIB directly binds PKA-C to promote its nuclear translocation and stimulates Akt Ser473 phosphorylation, linking cAMP/PKA signaling to PI3K/Akt pathway activation in cancer cells, while also inhibiting PKA-mediated phosphorylation of specific substrates such as HSP27 [PMID:19483721, PMID:27325557, PMID:40593489]. PKIB additionally interacts with the G-protein-coupled zinc receptor GPR39, from which it is released upon zinc stimulation to inhibit PKA, forming a negative-feedback loop that couples receptor signaling to PKA suppression [PMID:24869658]. Transcription of PKIB is induced by HIF1 under chronic hyperglycemia to impair pancreatic beta cell function through PKA inhibition, and by AR, GR, and MYCN in distinct cancer contexts to drive proliferation and therapy resistance [PMID:25704817, PMID:31289138, PMID:38030378, PMID:40593489]."},"prefetch_data":{"uniprot":{"accession":"Q9C010","full_name":"cAMP-dependent protein kinase inhibitor beta","aliases":[],"length_aa":78,"mass_kda":8.5,"function":"Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q9C010/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PKIB","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PKIB","total_profiled":1310},"omim":[{"mim_id":"606914","title":"PROTEIN KINASE, cAMP-DEPENDENT CATALYTIC, INHIBITOR BETA; PKIB","url":"https://www.omim.org/entry/606914"},{"mim_id":"605078","title":"TAR DNA-BINDING PROTEIN; TARDBP","url":"https://www.omim.org/entry/605078"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":248.3},{"tissue":"intestine","ntpm":87.1}],"url":"https://www.proteinatlas.org/search/PKIB"},"hgnc":{"alias_symbol":[],"prev_symbol":["PRKACN2"]},"alphafold":{"accession":"Q9C010","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9C010","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9C010-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9C010-F1-predicted_aligned_error_v6.png","plddt_mean":64.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PKIB","jax_strain_url":"https://www.jax.org/strain/search?query=PKIB"},"sequence":{"accession":"Q9C010","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9C010.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9C010/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9C010"}},"corpus_meta":[{"pmid":"15448002","id":"PMC_15448002","title":"Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15448002","citation_count":123,"is_preprint":false},{"pmid":"25704817","id":"PMC_25704817","title":"Feedback inhibition of CREB signaling promotes beta cell dysfunction in insulin resistance.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25704817","citation_count":64,"is_preprint":false},{"pmid":"22678061","id":"PMC_22678061","title":"Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22678061","citation_count":62,"is_preprint":false},{"pmid":"35642629","id":"PMC_35642629","title":"α Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibody-positive individuals.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35642629","citation_count":57,"is_preprint":false},{"pmid":"22781929","id":"PMC_22781929","title":"Transcriptional response of the bovine endometrium and embryo to endometrial polymorphonuclear neutrophil infiltration as an indicator of subclinical inflammation of the uterine environment.","date":"2012","source":"Reproduction, fertility, and development","url":"https://pubmed.ncbi.nlm.nih.gov/22781929","citation_count":38,"is_preprint":false},{"pmid":"25337835","id":"PMC_25337835","title":"Alterations of gene profiles in Leydig-cell-regenerating adult rat testis after ethane dimethane sulfonate-treatment.","date":"2015","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/25337835","citation_count":36,"is_preprint":false},{"pmid":"19483721","id":"PMC_19483721","title":"Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19483721","citation_count":35,"is_preprint":false},{"pmid":"31640099","id":"PMC_31640099","title":"Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer's Disease-Precursor Phenotypes, and Metabolic Morbidities.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/31640099","citation_count":35,"is_preprint":false},{"pmid":"32187820","id":"PMC_32187820","title":"microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB.","date":"2020","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/32187820","citation_count":27,"is_preprint":false},{"pmid":"27325557","id":"PMC_27325557","title":"PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells.","date":"2016","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/27325557","citation_count":25,"is_preprint":false},{"pmid":"10880337","id":"PMC_10880337","title":"Cloning and mapping of human PKIB and PKIG, and comparison of tissue expression patterns of three members of the protein kinase inhibitor family, including PKIA.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/10880337","citation_count":23,"is_preprint":false},{"pmid":"38486356","id":"PMC_38486356","title":"Comprehensive transcriptional atlas of human adenomyosis deciphered by the integration of single-cell RNA-sequencing and spatial transcriptomics.","date":"2024","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/38486356","citation_count":23,"is_preprint":false},{"pmid":"28387904","id":"PMC_28387904","title":"Study on correlation between PKIB and pAkt expression in breast cancer tissues.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28387904","citation_count":16,"is_preprint":false},{"pmid":"29727505","id":"PMC_29727505","title":"Integrated microRNA and mRNA sequencing analysis of age-related changes to mouse thymic epithelial cells.","date":"2018","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/29727505","citation_count":16,"is_preprint":false},{"pmid":"24869658","id":"PMC_24869658","title":"Protein kinase inhibitor β enhances the constitutive activity of G-protein-coupled zinc receptor GPR39.","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24869658","citation_count":15,"is_preprint":false},{"pmid":"23224602","id":"PMC_23224602","title":"PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype.","date":"2012","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/23224602","citation_count":14,"is_preprint":false},{"pmid":"31289138","id":"PMC_31289138","title":"Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.","date":"2019","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31289138","citation_count":11,"is_preprint":false},{"pmid":"34099512","id":"PMC_34099512","title":"Generation and Characterization of a Cell Type-Specific, Inducible Cre-Driver Line to Study Olfactory Processing.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34099512","citation_count":9,"is_preprint":false},{"pmid":"21180879","id":"PMC_21180879","title":"Transcriptional regulation of bidirectional gene pairs by 17-β-estradiol in MCF-7 breast cancer cells.","date":"2010","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/21180879","citation_count":9,"is_preprint":false},{"pmid":"38030378","id":"PMC_38030378","title":"Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.","date":"2024","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38030378","citation_count":9,"is_preprint":false},{"pmid":"34944753","id":"PMC_34944753","title":"A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma-Carcinoma Sequence.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34944753","citation_count":9,"is_preprint":false},{"pmid":"32676926","id":"PMC_32676926","title":"Downregulation of cAMP-Dependent Protein Kinase Inhibitor-b Promotes Preeclampsia by Decreasing Phosphorylated Akt.","date":"2020","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/32676926","citation_count":5,"is_preprint":false},{"pmid":"35817785","id":"PMC_35817785","title":"Genomic instability genes in lung and colon adenocarcinoma indicate organ specificity of transcriptomic impact on Copy Number Alterations.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35817785","citation_count":5,"is_preprint":false},{"pmid":"12584438","id":"PMC_12584438","title":"Physical map of the chromosome 6q22 region containing the oculodentodigital dysplasia locus: analysis of thirteen candidate genes and identification of novel ESTs and DNA polymorphisms.","date":"2002","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/12584438","citation_count":5,"is_preprint":false},{"pmid":"36072791","id":"PMC_36072791","title":"PKIB involved in the metastasis and survival of osteosarcoma.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36072791","citation_count":4,"is_preprint":false},{"pmid":"28669946","id":"PMC_28669946","title":"[Expression of cAMP-dependent protein kinase inhibitor beta in colorectal carcinoma and its clinical significance].","date":"2017","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/28669946","citation_count":4,"is_preprint":false},{"pmid":"36356085","id":"PMC_36356085","title":"Immune and Genomic Analysis of Boxer Dog Breed and Its Relationship with Leishmania infantum Infection.","date":"2022","source":"Veterinary sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36356085","citation_count":3,"is_preprint":false},{"pmid":"40593489","id":"PMC_40593489","title":"PKIB facilitates bladder cancer proliferation and metastasis through mediation of HSP27 phosphorylation by PKA.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40593489","citation_count":1,"is_preprint":false},{"pmid":"38731883","id":"PMC_38731883","title":"PKIB, a Novel Target for Cancer Therapy.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38731883","citation_count":1,"is_preprint":false},{"pmid":"39270811","id":"PMC_39270811","title":"Identification of competing endogenous RNA networks associated with circRNA and lncRNA in TCDD-induced cleft palate development.","date":"2024","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/39270811","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.27.623785","title":"Analysis of publicly available transcriptomic data to identify key genes and pathways associated with osteosarcoma metastasis","date":"2024-11-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.27.623785","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":17210,"output_tokens":2335,"usd":0.043327},"stage2":{"model":"claude-opus-4-6","input_tokens":5647,"output_tokens":2745,"usd":0.14529},"total_usd":0.188617,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"PKIB was cloned as a novel member of the human cAMP-dependent protein kinase inhibitor (PKI) gene family; the deduced protein contains both a pseudosubstrate site and a leucine-rich nuclear export signal motif, consistent with its role as an endogenous inhibitor of PKA catalytic activity. PKIB was mapped to chromosome 6q21-22.1 and shown to have two transcripts with distinct tissue expression patterns.\",\n      \"method\": \"cDNA cloning, Northern blot, radiation hybrid mapping\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cloning and structural domain identification with tissue expression characterization, single lab\",\n      \"pmids\": [\"10880337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PKIB directly interacts with the cAMP-dependent protein kinase A catalytic subunit (PKA-C); this interaction is required for nuclear translocation of PKA-C in prostate cancer cells. Additionally, PKIB promotes phosphorylation of Akt at Ser473 via PKA-C, as demonstrated by an in vitro kinase assay showing recombinant PKIB enhances PKA-C-mediated Akt phosphorylation. Knockdown of PKIB reduced nuclear PKA-C and decreased Akt-Ser473 phosphorylation, while PKIB overexpression enhanced it.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, exogenous overexpression, in vitro kinase assay, nuclear fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay plus reciprocal interaction plus functional KD/OE with defined biochemical readouts, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19483721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PKIB (protein kinase inhibitor β) was identified as a binding partner of the C-terminus of the G-protein-coupled zinc receptor GPR39 via yeast-two-hybrid screen. Co-expression of PKIB with GPR39 enhanced GPR39's constitutive protective activity via the Gα13/RhoA/SRE pathway. Zinc caused dissociation of PKIB from GPR39, liberating PKIB to associate with PKA and inhibit its activity, forming a negative-feedback loop. Mutation of PKIB's pseudosubstrate domain abolished PKA inhibition but did not affect GPR39 interaction or cell protection.\",\n      \"method\": \"Yeast-two-hybrid screen, co-expression functional assay, site-directed mutagenesis of pseudosubstrate domain, SRE-reporter assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — Y2H identification plus mutagenesis plus functional reporter assay, multiple orthogonal methods in single study\",\n      \"pmids\": [\"24869658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Chronic hyperglycemia activates HIF1-dependent transcription of PKIB in pancreatic islets, and PKIB acts as a potent inhibitor of PKA catalytic activity, thereby disrupting cAMP signaling and impairing beta cell function. Genetic disruption of the PKIB gene improved islet function in obese mice, placing PKIB downstream of HIF1 and upstream of PKA in this pathway.\",\n      \"method\": \"PKIB knockout mouse model, oral glucose tolerance test, islet functional assays, HIF1-dependent gene induction assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined physiological phenotype, genetic epistasis (HIF1→PKIB→PKA) supported by multiple assays\",\n      \"pmids\": [\"25704817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PKIB promotes cell proliferation and invasion-metastasis in NSCLC cells through activation of the PI3K/Akt signaling pathway; inhibition of PI3K/Akt abolished the pro-proliferative and pro-metastatic effects of PKIB overexpression, and knockdown of PKIB reduced Akt pathway activity.\",\n      \"method\": \"MTT assay, BrdU assay, western blot, migration/invasion assays, PI3K inhibitor epistasis experiment, siRNA knockdown and overexpression\",\n      \"journal\": \"Experimental biology and medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pathway epistasis via inhibitor plus KD and OE, single lab\",\n      \"pmids\": [\"27325557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PKIB expression in aromatase inhibitor-resistant breast cancer is regulated by androgen receptor (AR) downstream of androstenedione signaling; ChIP analysis demonstrated direct AR recruitment to the PKIB gene promoter, and re-exposure to estradiol suppressed PKIB expression.\",\n      \"method\": \"RNA sequencing, ChIP assay, cell viability assay, hormone treatment/withdrawal experiments\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP directly demonstrates AR binding to PKIB promoter, functional regulation confirmed by hormone manipulation, single lab\",\n      \"pmids\": [\"31289138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Downregulation of PKIB in placental trophoblasts decreases phosphorylated Akt and downstream proteins (MMP2, MMP9, GSK3β), resulting in impaired trophoblast migration, invasion, and vessel formation. PKIB knockdown by siRNA phenocopied preeclampsia-associated defects in HTR8/SVneo cells.\",\n      \"method\": \"siRNA knockdown, real-time cell analysis, tube formation assay, spheroid sprouting assay, western blot\",\n      \"journal\": \"Reproductive sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — clean KD with multiple functional readouts and defined biochemical mechanism via Akt pathway, single lab\",\n      \"pmids\": [\"32676926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In castration-resistant prostate cancer, GR (glucocorticoid receptor) transcriptional activity following androgen receptor signaling inhibition directly upregulates PKIB mRNA and protein, leading to nuclear accumulation of PKA catalytic subunit (PKA-c) and increased CREB phosphorylation. SGRM treatment reduced PKIB expression and delayed CRPC progression in xenograft models.\",\n      \"method\": \"Gene expression analysis, SGRM treatment in xenograft mouse model, PKA-c nuclear localization assessment, CREB phosphorylation western blot\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo xenograft plus biochemical readouts of PKA-c localization and CREB phosphorylation, single lab\",\n      \"pmids\": [\"38030378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PKIB disrupts PKA kinase activity in bladder cancer cells, resulting in decreased phosphorylation of HSP27 at serine residues 15, 78, and 82 (a PKA substrate). Additionally, the transcription factor MYCN directly binds the PKIB promoter to drive PKIB overexpression in bladder cancer, linking upstream transcriptional regulation to the PKA/HSP27 pathway.\",\n      \"method\": \"In vitro functional assays (proliferation, migration, invasion), in vivo tumorigenic model, western blot for HSP27 phosphorylation, promoter binding assay for MYCN\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic identification of a specific PKA substrate (HSP27) and upstream transcriptional regulator (MYCN), multiple methods, single lab\",\n      \"pmids\": [\"40593489\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PKIB is an endogenous inhibitor of the PKA catalytic subunit that contains a pseudosubstrate domain and a nuclear export signal; it directly binds PKA-C to suppress its activity and control its nuclear translocation, while also linking PKA signaling to oncogenic Akt (Ser473) phosphorylation, regulating specific PKA substrates such as HSP27, interacting with GPR39 at the plasma membrane to modulate cAMP feedback, and being transcriptionally induced by HIF1 (in hyperglycemia/islet dysfunction) and by AR/MYCN in cancer contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PKIB is an endogenous inhibitor of the cAMP-dependent protein kinase A catalytic subunit (PKA-C) that functions through a pseudosubstrate domain and a leucine-rich nuclear export signal to regulate PKA activity and subcellular localization [PMID:10880337, PMID:19483721]. PKIB directly binds PKA-C to promote its nuclear translocation and stimulates Akt Ser473 phosphorylation, linking cAMP/PKA signaling to PI3K/Akt pathway activation in cancer cells, while also inhibiting PKA-mediated phosphorylation of specific substrates such as HSP27 [PMID:19483721, PMID:27325557, PMID:40593489]. PKIB additionally interacts with the G-protein-coupled zinc receptor GPR39, from which it is released upon zinc stimulation to inhibit PKA, forming a negative-feedback loop that couples receptor signaling to PKA suppression [PMID:24869658]. Transcription of PKIB is induced by HIF1 under chronic hyperglycemia to impair pancreatic beta cell function through PKA inhibition, and by AR, GR, and MYCN in distinct cancer contexts to drive proliferation and therapy resistance [PMID:25704817, PMID:31289138, PMID:38030378, PMID:40593489].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Cloning of PKIB established it as a third member of the PKI gene family, resolving whether additional PKA inhibitor genes existed beyond PKIA and PKIG and revealing that PKIB encodes both a pseudosubstrate inhibitory domain and a nuclear export signal.\",\n      \"evidence\": \"cDNA cloning, Northern blot, and radiation hybrid mapping in human tissues\",\n      \"pmids\": [\"10880337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct demonstration of PKA inhibitory activity by recombinant PKIB protein\",\n        \"Nuclear export function of the NES motif was inferred from sequence homology, not tested experimentally\",\n        \"Tissue-specific functional relevance remained uncharacterized\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that PKIB physically binds PKA-C and is required for PKA-C nuclear translocation resolved how PKIB controls PKA localization; the finding that PKIB enhances PKA-C-mediated Akt Ser473 phosphorylation in vitro revealed an unexpected pro-oncogenic link between PKA inhibition and Akt activation.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown, overexpression, in vitro kinase assay, and nuclear fractionation in prostate cancer cells\",\n      \"pmids\": [\"19483721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PKIB promotes Akt phosphorylation by directly altering PKA-C substrate specificity or by an indirect mechanism was not resolved\",\n        \"In vivo validation of the PKIB–Akt axis was lacking\",\n        \"Structural basis of the PKIB–PKA-C interaction was not determined\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of GPR39 as a PKIB-binding partner established a receptor-level mechanism: PKIB is sequestered at GPR39 and released by zinc to inhibit PKA, creating a ligand-gated negative-feedback loop on cAMP signaling.\",\n      \"evidence\": \"Yeast-two-hybrid screen, co-expression functional assays, pseudosubstrate domain mutagenesis, and SRE-reporter assay\",\n      \"pmids\": [\"24869658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Endogenous PKIB–GPR39 interaction was not confirmed by co-IP from native tissue\",\n        \"Physiological tissue context for this feedback loop was not established\",\n        \"Whether other GPCRs similarly sequester PKI family members was unknown\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Genetic deletion of PKIB improved glucose tolerance in obese mice, establishing PKIB as a physiologically relevant PKA inhibitor in pancreatic islets and placing it in a HIF1→PKIB→PKA pathway that mediates hyperglycemia-induced beta cell dysfunction.\",\n      \"evidence\": \"PKIB knockout mouse model, oral glucose tolerance tests, islet functional assays, HIF1-dependent gene induction\",\n      \"pmids\": [\"25704817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PKIB deletion rescues beta cell mass versus function was not dissected\",\n        \"Relative contributions of PKIA and PKIG in islets were not addressed\",\n        \"Downstream PKA substrates mediating the islet phenotype were not identified\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Epistasis experiments in NSCLC cells showed that PKIB's pro-proliferative and pro-invasive effects depend on PI3K/Akt pathway activation, generalizing the PKIB–Akt connection beyond prostate cancer.\",\n      \"evidence\": \"PI3K inhibitor epistasis, siRNA knockdown, overexpression, proliferation, and invasion assays in NSCLC cells\",\n      \"pmids\": [\"27325557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The direct molecular step linking PKIB/PKA-C to PI3K/Akt activation was not defined\",\n        \"In vivo NSCLC tumor model validation was absent\",\n        \"Single-lab finding without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ChIP analysis demonstrated that the androgen receptor directly binds the PKIB promoter in aromatase inhibitor-resistant breast cancer, establishing the first defined transcription factor that directly drives PKIB expression in a therapy-resistance context.\",\n      \"evidence\": \"ChIP assay, RNA-seq, hormone manipulation in AI-resistant breast cancer cells\",\n      \"pmids\": [\"31289138\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of AR-driven PKIB on PKA activity in breast cancer was not measured\",\n        \"Whether PKIB is required for AI resistance was not tested by genetic depletion\",\n        \"Single-lab observation\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PKIB knockdown in trophoblasts reduced pAkt and downstream MMP2/MMP9, impairing migration, invasion, and tube formation, extending the PKIB–Akt axis to placental biology and suggesting a role in preeclampsia pathogenesis.\",\n      \"evidence\": \"siRNA knockdown, real-time cell analysis, tube formation and spheroid sprouting assays, western blot in HTR8/SVneo cells\",\n      \"pmids\": [\"32676926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No patient-derived tissue validation of PKIB downregulation in preeclampsia\",\n        \"Whether PKA catalytic activity is involved or the effect is PKA-independent was not tested\",\n        \"Single cell line study\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In CRPC, glucocorticoid receptor directly upregulates PKIB after AR inhibition, leading to nuclear PKA-C accumulation and CREB phosphorylation; pharmacologic GR antagonism reduced PKIB and delayed CRPC progression, identifying PKIB as a GR-dependent resistance mediator.\",\n      \"evidence\": \"Gene expression analysis, xenograft mouse model with SGRM treatment, PKA-C nuclear localization and pCREB western blot\",\n      \"pmids\": [\"38030378\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether PKIB is sufficient (not just necessary) for GR-driven CRPC resistance was not shown\",\n        \"The paradox of PKIB as a PKA inhibitor yet promoter of nuclear PKA-C and pCREB was not mechanistically resolved\",\n        \"Single-lab finding\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"PKIB was shown to suppress PKA-mediated HSP27 phosphorylation at serines 15, 78, and 82, identifying the first specific PKA substrate regulated by PKIB; MYCN was found to directly bind the PKIB promoter, adding a third oncogenic transcription factor driving PKIB expression.\",\n      \"evidence\": \"Western blot for HSP27 phospho-sites, promoter binding assay for MYCN, proliferation/migration/invasion assays, in vivo bladder cancer model\",\n      \"pmids\": [\"40593489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HSP27 dephosphorylation is the primary effector of PKIB-driven bladder cancer phenotypes was not tested\",\n        \"Single-lab finding without independent confirmation of MYCN–PKIB regulation\",\n        \"Structural basis for PKIB selectivity toward HSP27 phosphorylation versus other PKA substrates was not addressed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which PKIB, nominally a PKA inhibitor, simultaneously promotes nuclear PKA-C translocation and Akt Ser473 phosphorylation remains unresolved; whether these reflect direct allosteric effects on PKA-C, scaffolding functions, or context-dependent conformational switching is unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural or biophysical data on the PKIB–PKA-C complex exist\",\n        \"The paradox of PKA inhibition versus nuclear PKA-C accumulation has not been mechanistically reconciled\",\n        \"Whether PKIB functions differently from PKIA and PKIG in any biological context remains untested by direct comparison\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 4, 6, 7, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PRKACA\",\n      \"GPR39\",\n      \"AKT1\",\n      \"HSPB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}